Centinel Spine files for NYSE IPO

Centinel Spine Holdco has filed for an initial public offering and plans to list its shares on the New York Stock Exchange under the ticker symbol CNTL. The company is headquartered in West Chester, Pennsylvania and operates as a commercial-stage medical device maker focused exclusively on total disc replacement. The IPO filing marks a step toward accessing public equity markets to support its next phase of development.

Morgan Stanley (MS), Goldman Sachs (GS), Piper Sandler (PIPR), Canaccord Genuity and BTIG are named as underwriters for the offering. The selection of a multi-bank syndicate outlines the structure of the planned transaction, though the filing centers primarily on the company’s financial performance, product platform and intended use of proceeds.

For the six months ended June 30, 2026, Centinel Spine reported net income of $10.2 million on revenue of $85.2 million. This compares with a net loss of $503,000 on revenue of $60.1 million in the prior-year six‑month period. The figures in the filing highlight both higher revenue and a shift to profitability over the past year’s first half.

These results frame the company as a commercial-stage business with growing sales rather than an early pre-revenue operation. The filing presents the half‑year performance as a key data point for prospective investors evaluating the company ahead of the planned listing.

Centinel Spine describes itself as focused exclusively on total disc replacement and highlights its prodisc platform as its core technology. The company reports that prodisc has been used in more than 300,000 implantations worldwide. It also states that the platform is supported by more than 590 peer-reviewed clinical papers.

These statistics are presented in the filing to demonstrate the breadth of clinical use and published evidence associated with the prodisc system. Together, they position the product as an established option within the total disc replacement segment of the medical device market.

As of June 30, 2026, Centinel Spine’s U.S. commercial network included 48 sales-management and clinical-support professionals and more than 400 distributors. This network underpins distribution of its disc replacement products and supports surgeons and healthcare providers using the prodisc platform.

The company states that it intends to use proceeds from the IPO to repay debt and to invest in its sales infrastructure, patient-awareness programs and clinical trials. These planned allocations suggest a focus on strengthening the balance sheet while also expanding commercial reach and clinical evidence for its disc replacement technologies.